NOVN
Novan, Inc.
Set alert
52-week range unavailable
- Open
- 0.1368
- Prev close
- 0.0941
- Mkt cap
- 15.74M
- Vol
- 6.93M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.082
- High
- 0.1395
- Forward P/E
- -1.17
- Beta
- -0.04
- Short ratio
- 1.64
- Inst. own
- 6.86%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 10, 2023
- 50-d avg
- 0.89108
- 200-d avg
- 1.20
- 1y target
- 10.80
Key statistics
- Market cap
- 15.74M
- Enterprise value
- 40.21M
- Trailing P/E
- 0.00
- Forward P/E
- -1.17
- PEG ratio
- 0.00
- Price / sales
- 0.63
- Price / book
- 0.00
- EPS (TTM)
- -1.52
- Beta
- -0.04
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -128.61%
- Revenue (TTM)
- 24.92M
- Revenue growth
- 64.20%
- Free cash flow
- -31.32M
- Total cash
- 12.54M
- Total debt
- 36.77M
- Return on equity
- -2098.89%
- Shares outstanding
- 28.02M
- Short % of float
- 1.62%
- 50-day average
- 0.89108
- 200-day average
- 1.20
Analyst view
Consensus: buy
- Target (low)
- 6.00
- Target (mean)
- 10.80
- Target (high)
- 17.00
- Strong buy0
- Buy2
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 10, 2023
Expected Aug 10, 2023. Consensus EPS estimate -0.20.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 10, 2023 | Jun 1, 2023 | -0.09 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | -0.32 | — | — | — |
| Mar 30, 2023 | Dec 1, 2022 | -0.31 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -0.39 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -0.59 | — | — | — |
| May 16, 2022 | Mar 1, 2022 | -0.57 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 1, 2023 | Oppenheimer | down | Outperform | Perform |
| May 16, 2023 | Oppenheimer | main | Outperform | Outperform |
| Mar 31, 2023 | Cantor Fitzgerald | reit | — | Overweight |
| Aug 16, 2022 | HC Wainwright & Co. | main | — | Buy |
| Jul 19, 2022 | Oppenheimer | init | — | Outperform |
| Sep 24, 2021 | HC Wainwright & Co. | main | — | Buy |
About Novan, Inc.
Novan, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. The company was incorporated in 2006 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- novan.com
News
- Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
- Novartis AGcompleted the acquisition of Regulus Therapeutics Inc..
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket
- Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection
- Novan, Inc. (NOVN) Q1 2023 Earnings Call Transcript
- Earnings Scheduled For May 15, 2023
- Novan to Report First Quarter 2023 Financial Results on May 15, 2023
Your note
Sign in to keep a note on NOVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIERMAN JAMES L | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 40,101 |
| GAY JOHN M. | Chief Financial Officer | Conversion of Exercise of derivative security | Jun 6, 2023 | 46,831 |
| GEER W KENT | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 37,683 |
| KEEGAN ROBERT J | Director | Conversion of Exercise of derivative security | Jun 6, 2023 | 42,404 |
| MALIN LIFE SCIENCES HOLDINGS, LTD. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 1, 2019 | 0 |
| MARTIN G KELLY | Chief Executive Officer | Purchase | May 28, 2019 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 8.02% | 2,247,248 | 1.26M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 2.88% | 807,993 | 453.85K | Mar 30, 2023 |
| Blackrock Inc. | 1.08% | 302,312 | 169.81K | Mar 30, 2023 |
| B. Riley Wealth Advisors, Inc. | 0.67% | 187,000 | 105.04K | Mar 30, 2023 |
| Geode Capital Management, LLC | 0.54% | 150,451 | 84.51K | Mar 30, 2023 |
| Renaissance Technologies, LLC | 0.30% | 85,374 | 47.95K | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.95% | 545,361 | 306.33K | Dec 30, 2022 |
| Vanguard Extended Market Index Fund | 0.75% | 210,175 | 118.06K | Dec 30, 2022 |
| Fidelity Extended Market Index Fund | 0.29% | 81,805 | 45.95K | Feb 27, 2023 |
| iShares Micro Cap ETF | 0.15% | 41,291 | 23.19K | Feb 27, 2023 |
| Fidelity Series Total Market Index Fund | 0.10% | 27,734 | 15.58K | Feb 27, 2023 |
| Fidelity Total Market Index Fund | 0.07% | 20,460 | 11.49K | Feb 27, 2023 |